Norepinephrine contributes to antinociceptive, sedative, and sympatholytic responses in vivo, and ␣ 2 adrenergic receptor (␣ 2 AR) agonists are used clinically to mimic these effects. Lack of subtype-specific agonists has prevented elucidation of the role that each ␣ 2 AR subtype (␣ 2A , ␣ 2B , and ␣ 2C ) plays in these central effects. ␣ 2 -adrenergic receptors (␣ 2 ARs) present in the central nervous system (CNS) respond to norepinephrine (NE) and epinephrine and mediate sympatholytic, sedative-hypnotic, analgesic, anesthetic-sparing, hypotensive, and anxiolytic responses (1). Many of these responses are therapeutically useful and are exploited clinically, for example, during anesthesia and to attenuate the symptoms of opioid withdrawal (2). Three ␣ 2 AR subtypes have been revealed by pharmacological (␣ 2A AR, ␣ 2B AR, and ␣ 2C AR) and molecular cloning (␣ 2a AR, ␣ 2b AR, and ␣ 2c AR) strategies (3), and all couple, via pertussis toxin-sensitive G i ͞G o proteins, to attenuation of adenylyl cyclase, suppression of voltage-gated Ca 2ϩ channels, and activation of inwardly rectifying K ϩ channels (4). Multiple experimental limitations have precluded clarifying the involvement of each ␣ 2 AR subtype in catecholaminemediated physiological responses in the CNS. Subtype-specific ␣ 2 AR agonists and antagonists are not available (5); even when subtype selectivity has been noted in vitro, varying and unknown in vivo bioavailability precludes confident correlation of the administered dose with the amount of drug at the receptor site. Previous studies to explore ␣ 2 AR involvement in various responses have used prazosin to block catecholamine responses mediated by ␣ 1 adrenergic receptors (␣ 1 AR); however, it is now known that the ␣ 2B AR and ␣ 2C AR subtypes also are blocked by prazosin (5), thus confounding the interpretations of these earlier studies. In addition, because ␣ 1 AR can functionally antagonize ␣ 2 AR-mediated responses in some settings, ␣ 2 AR responses in the presence of prazosin (added to block ␣ 1 AR, ␣ 2B AR, and ␣ 2C AR) may reflect the disturbance of the balance between the functionally antagonistic ␣ 2 AR and ␣ 1 AR systems rather than provide insights concerning the role of the ␣ 2A AR subtype. Consequently, we manipulated the mouse genome to provide definitive evidence regarding the role of the ␣ 2A AR subtype in CNS responses.
␣ 2 -adrenergic receptors (␣ 2 ARs) present in the central nervous system (CNS) respond to norepinephrine (NE) and epinephrine and mediate sympatholytic, sedative-hypnotic, analgesic, anesthetic-sparing, hypotensive, and anxiolytic responses (1) . Many of these responses are therapeutically useful and are exploited clinically, for example, during anesthesia and to attenuate the symptoms of opioid withdrawal (2) . Three ␣ 2 AR subtypes have been revealed by pharmacological (␣ 2A AR, ␣ 2B AR, and ␣ 2C AR) and molecular cloning (␣ 2a AR, ␣ 2b AR, and ␣ 2c AR) strategies (3) , and all couple, via pertussis toxin-sensitive G i ͞G o proteins, to attenuation of adenylyl cyclase, suppression of voltage-gated Ca 2ϩ channels, and activation of inwardly rectifying K ϩ channels (4). Multiple experimental limitations have precluded clarifying the involvement of each ␣ 2 AR subtype in catecholaminemediated physiological responses in the CNS. Subtype-specific ␣ 2 AR agonists and antagonists are not available (5) ; even when subtype selectivity has been noted in vitro, varying and unknown in vivo bioavailability precludes confident correlation of the administered dose with the amount of drug at the receptor site. Previous studies to explore ␣ 2 AR involvement in various responses have used prazosin to block catecholamine responses mediated by ␣ 1 adrenergic receptors (␣ 1 AR); however, it is now known that the ␣ 2B AR and ␣ 2C AR subtypes also are blocked by prazosin (5) , thus confounding the interpretations of these earlier studies. In addition, because ␣ 1 AR can functionally antagonize ␣ 2 AR-mediated responses in some settings, ␣ 2 AR responses in the presence of prazosin (added to block ␣ 1 AR, ␣ 2B AR, and ␣ 2C AR) may reflect the disturbance of the balance between the functionally antagonistic ␣ 2 AR and ␣ 1 AR systems rather than provide insights concerning the role of the ␣ 2A AR subtype. Consequently, we manipulated the mouse genome to provide definitive evidence regarding the role of the ␣ 2A AR subtype in CNS responses.
We used the ''hit and run'' targeting variant of homologous recombination (6, 7) to substitute a subtle mutation of the ␣ 2a AR, D79N into the mouse genome as a tool to explore the role of the ␣ 2a AR in vivo (8) . The aspartate residue at position 79 (D79) is highly conserved in a topologically identical position in the second transmembrane span in a large subset of G protein-coupled receptors (9) . Mutation of this residue has been shown to eliminate allosteric regulation of receptor binding by monovalent cations (10) (11) (12) (13) and to perturb receptor-G protein-effector coupling (14) (15) (16) (17) in heterologous expression systems. Thus, the animals expressing the D79N ␣ 2a AR provide the opportunity to examine the functional importance of the ␣ 2A AR in a variety of complex physiological and behavioral responses.
EXPERIMENTAL PROCEDURES
Mouse Lines. The D79N mouse line was created using a hit and run gene targeting strategy (18) , as described (8) . Male chimeras were mated with C57BL͞6 mice to generate heterozygous mice for intercrosses. B6,129 hybrid offspring of wild-type (WT) and D79N breeding pairs were used in the present studies. Male chimeras also were mated with 129͞Sv females to establish the D79N mutation on a pure 129͞Sv background. These 129͞Sv D79N mice showed binding properties indistinguishable from those in the mixed genetic background (other functions not evaluated). In addition, the B6,129 heterozygous offspring of a chimera have been backcrossed against C57BL͞6 to establish the D79N mutation on a pure C57BL͞6 background (10 generations), and the mice have been made available to Jackson Laboratories (designated Adra2a tm1Lel ; #2-777). The purebred C57BL͞6 animals showed changes in receptor binding and in vivo sedative response indistinguishable from those on the mixed genetic background.
Rotarod and Loss of Righting Ref lex Tests. B6,129 male mice, Ϸ3 months old, were placed on a rotarod (IITC, Inc., Life Sciences, St. Petersburg, FL) turning at 10 revolutions per minute. The mice learned to remain on the rod during three 60-s training periods. Saline or increasing doses of dexmedetomidine (dex) were injected i.p.; after 10 min, each mouse was tested three times in succession for its ability to remain on the rod. The cutoff time was 60 s. After cumulative doses of dex (433 g͞kg) or pentobarbital (143 mg͞kg) during the rotarod test, the mice were gently rolled onto their backs; mice that failed to right themselves were considered nonresponsive. Sleep time was defined as the duration of loss of righting reflex (LORR). Researchers were blinded to the genotypes of the mice tested for this and subsequent functional tests.
Anesthetic-Sparing Effect. Groups of eight B6,129 male mice, Ϸ3 months old, were placed in an air-tight Plexiglas chamber with gloved access ports. Halothane (vol͞vol % in O 2 ) was continuously introduced, circulated, and monitored. Mice were equilibrated to each concentration of halothane for 40 min before testing for nonresponsiveness by LORR. After halothane concentrations that elicited LORR in the absence of exogenous drugs were established, drugs were injected i.p. and mice were tested for LORR after 30 min at the initial halothane concentration and 40 min after each change in halothane concentration.
Hot Plate Test. B6,129 male mice, Ϸ3 months old, were placed on an enclosed hot-plate (IITC Inc.); the temperature of the plate was ramped at 6°C͞min from 43°C to 52°C. When a mouse licked a hind paw, the mouse was removed from the hot plate and the temperature recorded. Each mouse was tested 10 min after i.p. saline or drug injections three times in succession.
NE Turnover. B6,129 male mice, Ϸ3 months old, were injected i.p. with saline or dex (100 g͞kg). After 30 min, the mice were killed by 30-s exposure to CO 2 , and the left hippocampus was isolated. Samples were sonicated in ice-cold 5% perchloric acid and centrifuged. The supernatant was filtered to exclude molecules exceeding 5000 kDa. The biogenic amines were assayed using HPLC͞electrochemical detection as described (19) .
Recording of Locus Ceruleus (LC) Neuronal Activity. Coronal brain slices of 200 m thickness containing the LC (20) were prepared from B6,129 mice Ϸ2-3 weeks old using techniques described (21) . Spontaneous action potentials, observed in LC neurons using the perforated patch technique, were amplified using an Axopatch 1D amplifier (Axon Instruments, Foster City, CA) and were recorded using the PCLAMP program (Axon Instruments) on a computer and on a Grass Instruments (Quincy, MA) chart recorder and PCM͞VCR. Drugs were delivered in the superfusing artificial cerebrospinal fluid containing 124 mM NaCl, 4.5 mM KCl, 1 mM MgCl 2 , 26 mM NaHCO 3 , 1.2 mM NaH 2 PO 4 , 10 mM D-glucose, and 2 mM CaCl 2 . To obtain the perforated-patch configuration, amphotericin B (200 g͞ml) was added to the internal solution, which contained 125 mM KMeSO 4 , 15 mM KCl, 1 mM MgCl 2 , 10 mM Hepes (pH 7.4), and 280 milliosmol final osmality. The firing rate and resting membrane potential of LC neurons generally were stable during the course of the experiments, which lasted 2-3 h.
Recording of Voltage-Gated Ca 2؉ Current. Acutely dissociated LC neurons from B6,129 mice Ϸ2-3 weeks old were prepared using enzymatic treatment (21) . No observable difference in morphology (22) was noticed between LC regions and isolated neurons of WT and mutant D79N mice. The neurons were superfused with external solution containing 150 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 10 mM Hepes, 10 mM D-glucose (pH 7.4), 340 milliosmol final osmality. After obtaining the whole cell patch-clamp configuration, the external solution was switched to a barium solution: 140 mM tetraethylammonium (TEA)-OH, 10 mM Hepes, 5 mM BaCl 2 , 15 mM D-glucose, and 0.5 M tetrodotoxin, pH 7.4) for current isolation. The current was elicited by delivering depolarizing pulses from holding potential Ϫ80 mV using an Axoclamp 1D amplifier and the PCLAMP program. Drugs were delivered near the neuron using an array of capillary pipes. The internal solution contained 125 mM N-methyl-D-glucamine, 20 mM TEA-OH, 10 mM Hepes, 11 mM EGTA, 1 mM CaCl 2 , 14 mM phosphocreatine, 4 mM Mg-ATP, 0.3 mM GTP, 10 mM HCl, pH 7.4. Superior cervical ganglion (SCG) neurons were isolated via enzymatic treatment (23) , and the current was recorded as for LC neurons.
Statistical Analysis. Group means were statistically compared using ANOVA, followed by the Tukey-Kramer multiple comparisons post hoc test, unless noted otherwise. 
RESULTS
We evaluated the ability of the ␣ 2 AR agonist dex to elicit sedation in D79N ␣ 2A AR mice by examining its effect on the ability of these mice to remain on a rotating bar. Dex dosedependently reduced the ability of WT mice to remain on the rotarod (Fig. 1A) , presumably by impairing motor coordination as a result of its sedative actions. Administration of the maximum dose of dex also elicited prolonged sleep time in WT mice (322 Ϯ 38 min) whereas dex neither reduced rotarod latency nor elicited sleep in D79N mice ( Fig. 1 A and B) even though dex bioavailability was similar in WT and D79N mice (plasma levels 30 min after injection: WT, 5.6 Ϯ 4.5 ng͞ml; D79N, 7.6 Ϯ 2.6 ng͞ml; n ϭ 5-7). In contrast to the findings for the ␣ 2 AR agonist dex, the non-␣ 2 AR-directed sedative agent, pentobarbital, induced comparable sleep times in WT and mutant mice (Fig. 1B) . Taken together, these findings suggest that the ␣ 2A AR subtype plays a critical role in mediating the sedative-hypnotic effects of adrenergic agonists.
A clinically useful action of ␣ 2 AR agonists is their ability to reduce dose requirements for other anesthetic agents (24, 25) . We evaluated the ability of dex to reduce the dose requirements for a volatile agent, halothane. In WT mice, doses of dex that were only minimally sedative in the rotarod test reduced the concentration of halothane required to elicit an anesthetic response (Fig. 1C) . In contrast, dex did not elicit halothanesparing activity in D79N ␣ 2A AR mice (Fig. 1C) . The anesthetic-sparing effects of the adenosine A 1 -receptor (A 1 adoR) agonist R-(2-phenylisopropyl)adenosine were indistinguishable in WT and D79N mice (Fig. 1D) , indicating that postreceptor signaling components, presumed to be common for ␣ 2 AR and A 1 adoR (26), are not perturbed in the mutant mice. These data provide strong evidence that the dysfunction in D79N ␣ 2A AR is not caused by secondary changes in signaling pathways and, further, that the ␣ 2A AR subtype plays the prominent role in volatile anesthetic-sparing responses.
The analgesic properties of ␣ 2 AR agonists add to their usefulness in the practice of anesthesiology (2, 27, 28) . We examined the analgesic properties of ␣ 2 AR agonists in attenuating thermally induced pain. Dex dose-dependently increased the thermal pain threshold of WT mice in the ramped hot plate test, which examines supraspinal pain perception, but had no effect on the pain threshold of D79N mice ( Fig. 2A) . In contrast, the -opioid receptor agonist morphine, a widely used analgesic agent coupled to signaling pathways similar to the ␣ 2 AR, increased the pain threshold of both WT and D79N mice with indistinguishable dose-response curves (Fig. 2 A) . These findings indicate that the pathways mediating antinociception after thermally induced pain are not altered in the D79N ␣ 2A AR mutant mice but that the mutation of the ␣ 2A AR has eliminated responses to ␣ 2 AR agonists.
To determine whether presynaptic effects of ␣ 2 AR were modified in vivo, basal turnover of NE was measured as the ratio of the NE metabolite 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) to NE, where MHPG reveals the fraction of neurotransmitter that has been released and metabolized in synaptic terminals after reuptake. The significantly elevated MHPG͞NE ratio in mutant mice (Fig. 2B) suggests that regulation of presynaptic events in the CNS has been modified in the D79N ␣ 2A AR mutant mice and that the ␣ 2A AR subtype contributes to mediation of presynaptic effects, corroborating the findings of Starke and colleagues (29, 30) . The retention of the ability of dex, although attenuated, to suppress the MHPG͞NE ratio in the D79N mutant mice is consistent with the interpretation that the ␣ 2A AR subtype is not exclusively involved in presynaptic regulation of NE release. Our studies, however, cannot ascertain whether or not the elimination of anesthetic and analgesic responses to ␣ 2 AR agonists we detect in the D79N mice are due to pre-or postsynaptic mechanisms, or both.
An unexpected finding was that mice homozygous for the D79N mutation exhibited a significant reduction (80%) in the functional density of ␣ 2A AR compared with the density of ␣ 2A AR in brain membranes from WT mice (8) . In contrast, the content of mRNA encoding the ␣ 2A AR subtype is indistinguishable in WT and D79N mice (8) as is the temporal and spatial expression of the mRNA encoding all three ␣ 2 AR subtypes (ref. 31 and R.-X. Wang and L.E.L., unpublished observations). Despite the reduction in functional ␣ 2A AR density, the specificity of binding characteristic of the ␣ 2A AR subtype was retained in the D79N mutant structure (Fig.  3A-C) . The loss of response to ␣ 2 AR agonists in D79N mice is not due to a reduced affinity of the D79N receptor for agonist ligands. In fact, because the D79N ␣ 2A AR lacks Na ϩ -elicited allosteric reduction in receptor affinity for agonists, the D79N receptor actually manifests an apparent increase in affinity for agonists, the extent of which correlates with agonist efficacy (efficiency of coupling agonist occupancy to response). Thus, the increase in agonist potency is greater for dex (Fig. 3B ) than for epinephrine (Fig. 3A) , and there is little effect on the affinity of the D79N receptor for the agonist͞partial agonist UK 14,304 (Fig. 3C ) when compared with agonist competition at the WT ␣ 2A AR. The fraction of functional ␣ 2A AR that remains in D79N mice does not appear to be coupled to G proteins, at least based on guanine nucleotide regulation of agonist binding (Fig. 3D) . No high affinity radiolabeled, guanine nucleotide-sensitive agonist binding was observed in D79N mice, even though we would have been able to detect 20% of the content of p-[ 125 I]iodoclonidine binding observed in WT mice, if the only change in ␣ 2A AR binding properties in D79N mice was an 80% reduction in binding capacity. Taken together, these findings indicate that the receptor properties are those expected for the D79N mutant ␣ 2A AR (11, 32) , with an unexpected reduction in the density of D79N ␣ 2A AR in vivo (8) .
We evaluated D79N ␣ 2A AR regulation of ion channels in LC neurons. The LC is the site for expression of ␣ 2 AR-mediated, sedative-hypnotic responses (33, 34) and participates in ␣ 2 ARinduced analgesic effect (35, 36) . In situ hybridization in the mouse brain has revealed dense ␣ 2A AR localization in the LC (31), thus facilitating electrical detection of ␣ 2A AR-expressing neurons. LC neurons fire spontaneous action potentials. Activation of ␣ 2A AR or -opioid receptors in the LC enhances outward K ϩ current through inwardly rectifying K ϩ channels, leading to neuronal hyperpolarization and consequent reduction in spontaneous firing frequency (37) (38) (39) . As shown in Fig.  4 A and C, the ␣ 2 AR agonist clonidine elicited a significant suppression of spontaneous firing rate recorded from LC neurons in the brain slice preparation from WT mice, which FIG. 2. Analgesic effects and norepinephrine turnover in WT and D79N mice. (A) Increasing doses of dex or morphine were administered before determining the thermal pain threshold in WT (triangles) and D79N (circles) mice during the ramped hot plate test; cutoff temperature for the hot plate was 52°C. Drug doses were cumulative; n ϭ 8 mice͞group. (B) NE turnover in the hippocampus was quantitated as the ratio of the major NE metabolite MHPG to NE after injection of saline (sal) or dex in WT or D79N mice; n ϭ 8 mice͞group. ‫,ء‬ significantly different WT vs D79N saline values (P Ͻ 0.01); #, significant difference between dex vs saline values for both groups (WT, P Ͻ 0.01; D79N, P Ͻ 0.05). Control turnover was defined as MHPG͞NE ratio in the hippocampus in the absence of any injection. was accompanied by detectable hyperpolarization in some neurons (Fig. 4A Inset) . In contrast, treatment of LC neurons from D79N mice failed to alter spontaneous firing rate or membrane potential, even at supramaximal concentrations of the ␣ 2 AR agonist ( Fig. 4 B and D) . (Clonidine, rather than dex, was used in these studies because its effects on brain slice preparations were more rapidly reversible.) The lack of response to exogenous agonist in D79N neurons was not due to a tonically active receptor population because ␣ 2 AR antagonists failed to influence spontaneous firing in mutant preparations (data not shown (Fig. 4 C and D) . The attenuation of spontaneous firing in the LC is attributed primarily to activation of inwardly rectifying K ϩ channels (37) (38) (39) , so the observation that the D79N ␣ 2A AR is unable to regulate LC neuronal firing suggests that the ␣ 2A AR cannot activate these K ϩ currents in D79N mice. Activation of ␣ 2 AR results in inhibition of voltage-gated Ca 2ϩ channels in many neuronal preparations. Suppression of these currents in LC neurons has been implicated in sedativehypnotic actions of ␣ 2 AR agonists (34) . A similar mechanism may underlie ␣ 2 AR-mediated anesthetic-sparing effects (40, 41) . Evaluation of ␣ 2 AR attenuation of voltage-gated Ca this response was dramatically reduced, however, in LC neurons derived from D79N mutant mice (Fig. 5 B and D) . The difference between ␣ 2A AR responses in WT and mutant neurons could not be attributed to any fundamental change in Ca 2ϩ current because the current-voltage relationship for Ca 2ϩ current was indistinguishable in both neuronal preparations (data not shown). In addition, DAMGO-mediated inhibition of Ca 2ϩ currents was similar in both WT and mutant neurons (Fig. 5 C and D) , indicating that the loss of regulation of Ca 2ϩ current by D79N ␣ 2A AR reflects a dysfunction of the mutant receptor rather than a fundamental change in the neuronal population or its regulation by other G i ͞G o -coupled receptors. The lack of effect of ␣ 2 AR antagonists on the Ca 2ϩ currents measured in either the WT or D79N preparations in the absence of agonist suggests that the responses noted are not influenced by the presence of endogenous agonist.
We also examined ␣ 2 AR-elicited suppression of voltagegated Ca 2ϩ current in SCG neurons. Stimulation of WT ␣ 2 AR with the agonists UK 14,304 (Fig. 5E) , clonidine, and dex (data not shown) produced significant inhibition of Ca 2ϩ currents in WT SCG neurons. The considerably attenuated ␣ 2 ARagonist-induced inhibition of Ca 2ϩ currents in SCG neurons from mutant mice was completely suppressed by prazosin (Fig.  5F ), an ␣ 1 AR antagonist that also blocks ␣ 2B AR and ␣ 2C AR subtypes (but not the ␣ 2A AR subtype) with reasonably high potency (5) , suggesting that the residual voltage-gated Ca 2ϩ current response to ␣ 2 AR agonists in neurons from D79N mice is mediated by ␣ 2B and͞or ␣ 2C AR subtype. Thus, the D79N mutant ␣ 2A AR is unable to evoke inhibition of voltage-gated Ca 2ϩ currents in SCG neurons, similar to the loss of responses observed in LC neurons derived from D79N mutant mice. In contrast, the somatostatin receptor, another Gi͞Go-coupled receptor, evoked a similar degree of Ca 2ϩ current suppression in both WT and mutant SCG neuronal preparations (Fig. 5 E  and F) , again indicating that the D79N mutation results in loss of ␣ 2A AR response without perturbation of shared downstream G protein or effector pathways.
DISCUSSION
The present study provides definitive evidence that the ␣ 2A subtype of ␣ 2 AR mediates clinically relevant sedativehypnotic, analgesic, and anesthetic-sparing responses in the mouse. In the absence of subtype-specific agonists and antagonists for the three ␣ 2 AR subtypes (5), manipulation of the mouse genome provides an alternative and, at present, the sole approach for defining the role of particular receptor subtypes in in vivo responses. An earlier study implicating the ␣ 2a AR subtype in sedative responses used antisense strategies to attenuate ␣ 2A AR vs ␣ 2C AR expression; however, the antisense oligonucleotides directed against the ␣ 2a AR subtype only reduced, but did not abolish, the sedative response, and thus the role of another ␣ 2 AR subtype in the residual response could not be precluded (42) . In contrast, the data from D79N ␣ 2A AR mice established the ␣ 2A AR subtype as the predominant, and likely the only, subtype mediating the sedativehypnotic response.
Involvement of the ␣ 2A AR subtype in the analgesic response has been suggested on the basis of a comparison of the efficacy of nonsubtype-specific ␣ 2 AR agents in producing the response in vivo and the affinity of these agents in interacting with the receptor in vitro (43) . However, variability in distribution and bioavailability of ␣ 2 AR agents could not be controlled in this study and may have confounded the interpretations, a limitation acknowledged by the authors (43) . In comparison, the present studies, which exploit a genetic approach, have unequivocally demonstrated that the ␣ 2A AR subtype mediates analgesic effects of ␣ 2 AR agonists in attenuating thermal pain perception. The complete loss of response to ␣ 2 AR agonists in sedative and analgesic paradigms indicates that the ␣ 2B and͞or ␣ 2C AR do not contribute to these responses; otherwise, they would have been able to compensate for the D79N ␣ 2A AR mutation.
It is of interest that a single ␣ 2 AR subtype is pivotal for both sedative and analgesic effects, especially because the proposed sites for these actions of ␣ 2 AR differ significantly. The LC has been implicated in the sedative effect of ␣ 2 AR agonists (33) , and the analgesic response to ␣ 2 AR agonists occurs via both supraspinal (including the LC) and spinal loci (36, 44, 45) . Our studies indicate that mutation of the ␣ 2A AR eliminates sedative-hypnotic as well as analgesic responses to ␣ 2 AR agonists without causing a general perturbation of the neural system because other non-␣ 2 AR-directed agents produce expected physiological and electrophysiological responses. (E and F) Percentage inhibition of the Ca 2ϩ current in WT and D79N SCG neurons by UK 14,304 in the absence and presence of the ␣1AR, ␣2BAR, and ␣2CAR antagonist prazosin and by somatostatin. The numbers of neurons tested were: UK 14,304, 7-14; UK 14,304 plus prazosin, 3-7; and Som, 3-8. ‫,ء‬ significantly different WT vs D79N value for the same treatment (P Ͻ 0.01). Notice that Ͼ80% of the UK 14,304-mediated response in WT is insensitive to 1 M prazosin, consistent with an ␣2AAR response. In contrast, much of the residual UK 14,304 suppression of Ca 2ϩ current in D79N mice is prazosinsensitive, perhaps reflective of ␣2B or ␣2CAR mediation of UK 14,304 effects in this setting. The findings from electrophysiological studies provide direct evidence that the D79N ␣ 2A AR is unable to activate inwardly rectifying K ϩ channels and to inhibit voltage-gated Ca 2ϩ channels. Whether the loss of D79N ␣ 2A AR modulation of these effector systems in vivo is due to a perturbation of receptor-G protein coupling by the mutation, as observed in these studies (cf. Fig. 3D ) as well as under in vitro conditions (14) , or is due to the Ϸ80% reduction in D79N ␣ 2A AR binding sites in the mutant mice without alteration in the quantity of mRNA encoding the WT vs D79N ␣ 2A AR (8) is not known. It is likely that the selective uncoupling of the D79N ␣ 2A AR to K ϩ channels observed in AtT20 cells, compared at equivalent WT and mutant ␣ 2A AR density (16, 17) , was not observed here because of the unexpected but marked reduction in the D79N ␣ 2A AR functional binding capacity in vivo. However, because physiological responses in vivo differ in their requirement for ␣ 2 AR occupancy (46), the reduction in ␣ 2A AR density in mutant mice will affect physiological responses differently, making it difficult to determine the relative contribution of receptor density vs altered receptor-G protein coupling to the loss of various responses in the D79N ␣ 2A AR mutant mice.
In summary, the present study provides definitive evidence that the ␣ 2A AR subtype is the primary mediator of the sedative, analgesic, and anesthetic-sparing responses to ␣ 2 AR agonists and also participates in presynaptic autoinhibition of neurotransmitter release. Although we cannot assign an unequivocal molecular explanation (i.e., loss of receptor density or G protein communication or both) for the loss of each of the electrical, cellular, and physiological responses evaluated in these studies, the present functional findings indicate that the D79N ␣ 2A AR mutant mice provide a powerful tool for elucidating the role of the ␣ 2A AR subtype in complex and diverse physiological responses in vivo, an essential prelude for the design of subtype-selective therapeutic agents.
